Observations placeholder
Daytrana
Identifier
018849
Type of Spiritual Experience
Number of hallucinations: 19
Background
A description of the experience
Daytrana is a medicinal patch developed and marketed by Noven Pharmaceuticals, Inc. that was approved in April 2006. In the literature, Daytrana is most commonly referred to as methylphenidate transdermal system (MTS).
Daytrana is approved by the Food and Drug Administration (FDA) as a once daily treatment of pediatric patients—ages 6 to 17—with attention deficit hyperactivity disorder (ADHD). However, off-label prescriptions in older patients are not uncommon. It is mainly prescribed as a second-line treatment for ADHD when traditional oral forms are not well-tolerated or if patients have difficulty with compliance.
On Jan, 05, 2017 11,115 people reported to have side effects when taking Daytrana.
Among them, 19 people (0.17%) have Hallucination
Time on Daytrana when people have Hallucination :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Hallucination | 42.86% | 28.57% | 0.00% | 28.57% | 0.00% | 0.00% | 0.00% |
Gender of people who have Hallucination when taking Daytrana :
| Female | Male | |
| Hallucination | 42.86% | 57.14% |
Age of people who have Hallucination when taking Daytrana :
0-12-910-1920-2930-3940-4950-5960+ Hallucination0.00%14.29%85.71%0.00%0.00%0.00%0.00%0.00%